8Suppliers
16Customers
2Debt Items
20Related Chains

Source-Backed Evidence Depth

Nuo Therapeutics, Inc. (AURX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.

27Total relationships
5Distinct source URLs
17High confidence
0.791Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.

Nuo Therapeutics, Inc. Suppliers

TickerNameConfidenceEvidence
PAUL-ANTHONY-JACOBS PAUL-ANTHONY-JACOBS 90% Mr. Jacobs loaned $300,000 in the Initial Funding and did not commit to loaning additional funds in a Second Funding.
PFE Pfizer Inc. 90% Reciprocal relationship from PFE graph: Reciprocal relationship from AURX graph: a reagent, bovine thrombin, is available exclusively through Pfizer, with whom we have an existing supply agreement
PFE Pfizer Inc. 90% a reagent, bovine thrombin, is available exclusively through Pfizer, with whom we have an existing supply agreement
SCOTT-M-PITTMAN SCOTT-M-PITTMAN 90% Mr. Pittman loaned $200,000 in the Initial Funding and committed to loaning $210,000 in a Second Funding, if any.
AN-AFFILIATE-OF-AN-EXISTING-DISTRIBUTOR-OF-THE-C AN-AFFILIATE-OF-AN-EXISTING-DISTRIBUTOR-OF-THE-C 80% The other Lenders consist of an affiliate of an existing distributor of the Company's Aurix product and a third party unaffiliated with the Company.
CONTRACT-MANUFACTURERS CONTRACT-MANUFACTURERS 80% We outsource the manufacturing of various product components to contract manufacturers
SNNUF Smith & Nephew plc 72% Reciprocal relationship from SNNUF graph: Reciprocal relationship from AURX graph: quity capital was accessed in December 2021 via the early exercise of warrants under a warrant modification agreemen…
SNNUF Smith & Nephew plc 72% quity capital was accessed in December 2021 via the early exercise of warrants under a warrant modification agreement. Distribution Agreement with Smith+Nephew On March 31, 2025, we entered into a Di…

Nuo Therapeutics, Inc. Customers

TickerNameConfidenceEvidence
AN-AFFILIATE-OF-AN-EXISTING-DISTRIBUTOR-OF-THE-C AN-AFFILIATE-OF-AN-EXISTING-DISTRIBUTOR-OF-THE-C 90% The other Lenders consist of an affiliate of an existing distributor of the Company's Aurix product
CUSTOMER-A CUSTOMER-A 90% Customer A 19 % - Customer B * 18 % Customer C * 15 % Customer D * 12 %
CUSTOMER-B CUSTOMER-B 90% Customer A 19 % - Customer B * 18 % Customer C * 15 % Customer D * 12 %
CUSTOMER-C CUSTOMER-C 90% Customer A 19 % - Customer B * 18 % Customer C * 15 % Customer D * 12 %
CUSTOMER-D CUSTOMER-D 90% Customer A 19 % - Customer B * 18 % Customer C * 15 % Customer D * 12 %
NEPHEW-PLC NEPHEW-PLC 85% in private office settings while continuing to engage with hospitals and hospital systems regarding expanded POS 22 usage while ensuring that the reimbursement mechanisms are appropriately administer…
SNNUF Smith & Nephew plc 85% Reciprocal relationship from SNNUF graph: Reciprocal relationship from AURX graph: Reciprocal relationship from SNNUF graph: Reciprocal relationship from AURX graph: Reciprocal relationship from SNNU…
SNNUF Smith & Nephew plc 85% quity capital was accessed in December 2021 via the early exercise of warrants under a warrant modification agreement. Distribution Agreement with Smith+Nephew On March 31, 2025, we entered into a Di…
AGX Argan, Inc. 62% Reciprocal relationship from AGX graph: Reciprocal relationship from AURX graph: e words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “will,” “will be,” “will continue,” “will likely resu…
ANALYSIS-GROUP ANALYSIS-GROUP 62% e words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “will,” “will be,” “will continue,” “will likely result,” “could,” “may” and words of similar import. These statements reflect the Com…
AUTOLOGOUS-WOUND-THERAPY-INC AUTOLOGOUS-WOUND-THERAPY-INC 62% ance - - 149,635 - 149,635 Net loss - - - ( 618,466 ) ( 618,466 ) Balance, March 31, 2026 48,289,296 $ 4,829 $ 34,001,936 $ ( 35,390,628 ) $ ( 1,383,863 ) Common Stock Shares Amount (par $0.0001) Add…
INFORMATIX-HOLDINGS-INC INFORMATIX-HOLDINGS-INC 62% ance - - 149,635 - 149,635 Net loss - - - ( 618,466 ) ( 618,466 ) Balance, March 31, 2026 48,289,296 $ 4,829 $ 34,001,936 $ ( 35,390,628 ) $ ( 1,383,863 ) Common Stock Shares Amount (par $0.0001) Add…
OTC-MARKETS-GROUP OTC-MARKETS-GROUP 62% of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also …
PUBLIC-REPORTING-COMPANY PUBLIC-REPORTING-COMPANY 62% of our business operations, if, as a result of actual or threatened patent infringement claims, we are unable to enter into licenses on acceptable terms. All of the issues described above could also …
SORIN-GROUP-USA-INC SORIN-GROUP-USA-INC 62% ance - - 149,635 - 149,635 Net loss - - - ( 618,466 ) ( 618,466 ) Balance, March 31, 2026 48,289,296 $ 4,829 $ 34,001,936 $ ( 35,390,628 ) $ ( 1,383,863 ) Common Stock Shares Amount (par $0.0001) Add…
SUCCESSFULLY-AFFECT-SUCH-FINANCING-COULD-BE-LIMI SUCCESSFULLY-AFFECT-SUCH-FINANCING-COULD-BE-LIMI 62% e is not part of this Annual Report. 6 Table of Contents ITEM 1A. Risk Factors An investment in the Company involves a high degree of risk. Before making an investment decision with respect to our co…

Nuo Therapeutics, Inc. Debt Obligations

InstrumentDescriptionConfidenceEvidence
AURX-DEBT-7982 Warrants outstanding: 6363638 90% xbrl warrant detail from xbrl 2025-12-31.
AURX-DEBT-7983 Xbrl Convertible 90% xbrl convertible detail from xbrl 2020-12-31.

Nuo Therapeutics, Inc. Acquisitions

No acquisitions on recordNo completed or pending acquisitions found in our database for Nuo Therapeutics, Inc..

Nuo Therapeutics, Inc. Ownership

HolderNameConfidenceEvidence
AURX-OWNER-ANCORA-ADVISORS-LLC Ancora Advisors LLC 90% 13F overlay lists Ancora Advisors LLC as top holder; 1 tracked holders.

Nuo Therapeutics, Inc. Extended Supply Chain Network

TickerNameChain IndexHopsRelationship Types
EW Edwards Lifesciences Corporation 100.00 2
IART Integra LifeSciences Holdings Corporation 100.00 2
JNJ Johnson & Johnson 100.00 2
MDWD MediWound Ltd. 100.00 2
DEO Diageo plc 100.00 2
PFE Pfizer Inc. 100.00 1 ['supplier']
IHG InterContinental Hotels Group PLC 100.00 2
AGX Argan, Inc. 100.00 1 ['customer']
CUPR Cuprina Holdings (Cayman) Limited 100.00 2
RLAY Relay Therapeutics, Inc. 50.00 2
SPRO Spero Therapeutics, Inc. 50.00 2
HBIO Harvard Bioscience, Inc. 50.00 2
ESPR Esperion Therapeutics, Inc. 50.00 2
ITGR Integer Holdings Corporation 50.00 2
NVAX Novavax, Inc. 50.00 2
CELC Celcuity Inc. 50.00 2
ESGL ESGL Holdings Limited 50.00 2
NRIX Nurix Therapeutics, Inc. 50.00 2
MDXG MiMedx Group, Inc. 50.00 2
ITRM Iterum Therapeutics PLC 50.00 2
🔐
AURX
Unlock AURX Supply Chain Data
Verified relationships include:
PAUL-ANTHONY-JACOBSPAUL-ANTHONY-JACOBSSupplier90%
PFEPfizer Inc.Supplier90%
AN-AFFILIATE-OF-AN-EXISTING-DISTRIBUTOR-OF-THE-CAN-AFFILIATE-OF-AN-EXISTI…Customer90%
CUSTOMER-ACUSTOMER-ACustomer90%
+23 more relationships locked
Subscribe — View plans →